col blocks we are bridge builder col blocks
COVID answers in Scientific Journals all over the world


31 Results       Page 1

 [1] 
Mediar Press: Rheumatology Science and Practice
  original article Date Title Authors   All Authors
1 [GO] 2024―Mar―05 Risk factors for severe COVID-19 in patients with rheumatic diseases A. N. Kulikov, N. V. Muravyeva, B. S. Belov
2 [GO] 2024―Mar―05 Coronavirus disease 2019 (COVID-19) pandemic and autoimmune rheumatic diseases: Outcomes and prospects E. L. Nasonov
3 [GO] 2023―Dec―27 Frequency and course of COVID-19 in patients with rheumatic diseases (according to the data of V.A. Nasonova Research Institute of Rheumatology) A. N. Kulikov, N. V. Muravyeva, B. S. Belov
4 [GO] 2023―Aug―31 Rheumatoid arthritis and COVID-19: Three years later B. S. Belov, E. S. Aronova, G. I. Gridneva, E. I. Nasonov
5 [GO] 2023―Mar―23 COVID-19 in a patient with granulomatosis with polyangiitis: Management tactics E. F. Iskhakova, E. V. Sukhorukova, M. Yu. Badeeva, E. V. Dyakova, S. A. Lapshina, T. V. Beketova, D. I. Abdulganieva
6 [GO] 2023―Mar―23 Multifocal osteonecrosis as a consequence of a new coronavirus infection A. A. Klimenko, N. A. Demidova, D. Yu. Andryashkina, N. M. Babadayeva, A. A. Kondrashov, Yu. M. Saakyan
7 [GO] 2023―Mar―23 Results of a 12-week open-label, non-interventional study of the efficacy and safety of olokizumab therapy in patients with rheumatoid arthritis after switching from anti-B-cell therapy during the SARS-CoV-2 pandemic A. A. Akimova, N. E. Banshchikova, A. E. Sizikov, A. A. Mullagaliev, E. A. Letyagina, N. A. Ilina, et al. (+6)
8 [GO] 2022―Dec―26 Avascular necrosis of the epiphyses of bones in patients who have had SARS-CoV-2 infection: Clinical observations and a narrative review of literature data V. E. Bialik, A. E. Karateev, E. I. Bialik, M. A. Makarov, S. A. Makarov, A. A. Roskidailo, et al. (+3)
9 [GO] 2022―Sep―08 COVID-19 in women with ankylosing spondylitis during pregnancy and within one year after childbirth O. A. Krichevskaya, T. V. Dubinina, E. V. Ilinykh, A. B. Demina, I. A. Andrianova
10 [GO] 2022―Jul―11 Features of the course and outcomes of COVID-19 in patients with axial spondyloarthritis Sh. F. Erdes
11 [GO] 2022―Jul―11 Autoantibodies and SARS-CoV-2 infection: A case report T. I. Kalenchic, S. L. Kabak, I. V. Korenevskaya
12 [GO] 2022―May―16 Interleukin 18 in Immune-mediated rheumatic diseases and COVID-19 E. L. Nasonov, A. S. Avdeeva
13 [GO] 2022―May―16 On the issue of post COVID-19 condition in patients with rheumatic diseases M. F. Beketova, V. V. Babak, M. D. Suprun, T. V. Beketova, O. A. Georginova
14 [GO] 2022―May―16 The use of biological disease-modifying antirheumatic drugs and Janus kinase inhibitors in rheumatoid arthritis during the COVID-19 coronavirus disease pandemic: data from a telephone survey of 254 patients A. E. Karateev, E. Yu. Polishchuk, A. S. Potapova, E. V. Matyanova, A. S. Semashko, А. O. Bobkova, et al. (+5)
15 [GO] 2022―May―16 Effect of COVID-19 coronavirus infection on the course of rheumatoid arthritis V. N. Sorotskaya, A. O. Plakhova, B. B. Halmuradova, D. S. Vaisman, R. M. Balabanova
16 [GO] 2022―Mar―02 Vaccination against SARS-CoV-2 in rheumatic diseases: Safety issues B. S. Belov, A. M. Lila, E. L. Nasonov
17 [GO] 2021―Dec―27 Course and outcomes of COVID-19 in patients with immunoinflammatory rheumatic diseases: Preliminary data from the NIIR/APP-COVID-19 registry and literature review E. L. Nasonov, B. S. Belov, A. M. Lila, E. S. Aronova, G. I. Gridneva, A. V. Kudryavtseva, et al. (+5)
18 [GO] 2021―Dec―27 Anxiety, depression and stress tension screening in patients with rheumatic and musculoskeletal diseases at the onset of the 2019 coronavirus disease (COVID-19) pandemic A. B. Borisova, T. A. Lisitsyna, D. Yu. Veltishchev, E. L. Nasonov
19 [GO] 2021―Sep―06 B cell depletion in immune-mediated rheumatic diseases and coronavirus disease 2019 (COVID-19) E. L. Nasonov, A. S. Avdeeva
20 [GO] 2021―Jul―15 Coronavirus Disease 2019 (COVID-19) and Immune-mediated Rheumatic Diseases. Recommendations of the Association of Rheumatologists of Russia E. L. Nasonov, A. M. Lila, V. I. Mazurov, B. S. Belov, A. E. Karateev, T. V. Dubinina, et al. (+5)
21 [GO] 2021―May―13 Problems of early diagnosis of systemic lupus erythematosus during the COVID-19 pandemic E. L. Nasonov, T. V. Popkova, T. A. Panafidina
22 [GO] 2021―Mar―03 Coronavirus disease 2019 (COVID-19) and autoimmunity E. L. Nasonov
23 [GO] 2021―Mar―03 COVID-19 and rheumatology: A year later B. S. Belov, A. M. Lila
24 [GO] 2021―Mar―03 The course and outcomes of COVID-19 in patients with ANCA-associated systemic vasculitis, receiving biological therapy (Rituximab, Mepolizumab): The results of the first 8 months of the pandemic T. V. Beketova, V. V. Babak, M. D. Suprun
25 [GO] 2021―Jan―15 Remote monitoring of patients with axial spondyloarthritis during the COVID-19 pandemic: results and prospects of using the information technology “Aspine” D. G. Rumiantceva, A. M. Lila, Sh. Erdes
26 [GO] 2020―Nov―10 Coronavirus Desease 2019 (COVID-19) in Children: Lessons from Pediatric Rheumatology M. I. Kaleda, I. P. Nikishina, E. S. Fedorov, E. L. Nasonov
27 [GO] 2020―Sep―09 Coronavirus disease 2019 (COVID-19) and immune-mediated inflammatory rheumatic diseases: at the crossroads of thromboinflammation and autoimmunity E. L. Nasonov, T. V. Beketova, T. M. Reshetnyak, A. M. Lila, L. P. Ananieva, T. A. Lisitsyna, S. K. Soloviev
28 [GO] 2020―Sep―09 Covid-19 in a patient with ANCA-associated systemic vasculitis, receiving anti-B cell therapy (rituximab) T. V. Beketova, L. M. Blank, A. M. Lila
29 [GO] 2020―Jun―24 DO NSAIDS CAUSE SPECIFIC COMPLICATIONS IN COVID-19 CORONAVIRUS INFECTION? A. E. Karateev, E. L. Nasonov, A. M. Lila
30 [GO] 2020―Jun―24 IMMUNOPATHOLOGY AND IMMUNOPHARMACOTHERAPY OF CORONAVIRUS DISEASE 2019 (COVID-19): FOCUS ON INTERLEUKIN 6 E. L. Nasonov
31 [GO] 2020―Apr―27 CORONAVIRUS DISEASE 2019 (COVID-19): A RHEUMATOLOGIST’S THOUGHTS E. L. Nasonov
 [1] 

31 Results       Page 1



[de][en]

Last change 2023―Oct―27 12:08:13 UTC

© Daten-Quadrat 2022       Done in 0.008 sec